Angion Announces Participation in Upcoming Investment Conferences

Rhea-AI Summary

Angion Biomedica Corp. (NASDAQ:ANGN) announced its participation in two upcoming investment conferences in March 2022, focusing on fibrotic diseases. Dr. Jay Venkatesan, the company's President and CEO, will join a kidney disease/fibrosis panel at the Cowen 42nd Annual Healthcare Conference on March 9 and a Fireside Chat at the Oppenheimer 32nd Annual Healthcare Conference on March 15. Webcasts from these events will be available for 30 days on Angion’s website.

UNIONDALE, N.Y., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, today announced participation in two upcoming investment conferences.

Angion will participate in two investment conferences in March. At the Cowen 42^nd Annual Healthcare Conference, Angion’s President and CEO Dr. Jay Venkatesan will participate in a kidney disease/fibrosis panel. At the Oppenheimer 32^nd Annual Healthcare Conference, Dr. Venkatesan will participate in a Fireside Chat with Oppenheimer Senior Biotech Analyst Justin Kim. Details are as follows:

Cowen 42^nd Annual Healthcare Conference (Virtual)

• Kidney Disease/Fibrosis Panel on Wednesday, March 9 starting at 2:10pm EST
  

Oppenheimer 32^nd Annual Healthcare Conference (Virtual)

• Fireside chat with Oppenheimer Senior Biotech Analyst Justin Kim on Tuesday, March 15 from 3:20-3:50pm EST
  

Webcasts of both events will be accessible online by visiting the events and presentations page under the investors section of Angion’s website at https://ir.angion.com/events-presentations. The webcasts will remain archived on Angion’s website for approximately 30 days.

About Angion Biomedica Corp.
Angion is committed to transforming the treatment paradigm for patients suffering from fibrotic diseases for which there are no approved medicines or where existing approved medicines have known limitations. Angion’s lead product candidate is ANG-3070, a highly-selective oral tyrosine kinase receptor inhibitor in development for the treatment of fibrotic kidney and lung diseases. Enrollment is ongoing in a dose-finding Phase 2 trial of ANG-3070 in primary proteinuric kidney diseases (NCT04939116). Additionally, Angion has preclinical programs focused on a rho kinase 2 (ROCK2) inhibitor and a CYP11B2 (aldosterone synthase) inhibitor. For more information, please visit www.angion.com.

Contact
David Miller
Director of Communications & Investor Relations
investors@angion.com

FAQ

What events is Angion Biomedica participating in March 2022?

Angion Biomedica is participating in the Cowen 42nd Annual Healthcare Conference on March 9 and the Oppenheimer 32nd Annual Healthcare Conference on March 15.

Who will represent Angion Biomedica at the healthcare conferences?

Dr. Jay Venkatesan, the President and CEO of Angion Biomedica, will represent the company at both conferences.

Where can I find the webcasts of Angion's conference participation?

Webcasts of Angion's participation will be accessible on their events and presentations page for 30 days.

What is Angion Biomedica focused on?

Angion Biomedica focuses on developing therapeutics for fibrotic diseases, with their lead product candidate being ANG-3070.

What is ANG-3070 being developed for?

ANG-3070 is being developed for the treatment of fibrotic kidney and lung diseases.